All Outputs (8)

Prebiotics for people with cystic fibrosis (2022)
Journal Article
Williams, N., Jayaratnasingam, J., Prayle, A. P., Nevitt, S. J., & Smyth, A. R. (2022). Prebiotics for people with cystic fibrosis. Cochrane Database of Systematic Reviews, 2022(12), Article CD015236. https://doi.org/10.1002/14651858.cd015236

Background. Description of the condition. Cystic fibrosis (CF) is a life‐limiting genetic disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. It affects approximately 100,000 children and adults worldwi... Read More about Prebiotics for people with cystic fibrosis.

Do guidelines for treating chest disease in children use Cochrane Reviews effectively?: a systematic review (2017)
Journal Article
Prayle, A., Cox, T., Smith, S., Rycroft-Malone, J., Thomas, K. S., Hughes, D. A., & Smyth, A. R. (in press). Do guidelines for treating chest disease in children use Cochrane Reviews effectively?: a systematic review. Thorax, https://doi.org/10.1136/thoraxjnl-2016-208790

Cochrane Reviews summarise best evidence and should inform guidelines. We assessed the use of Cochrane Reviews in the UK guidelines for paediatric respiratory disease. We found 21 guidelines which made 1025 recommendations, of which 96 could be infor... Read More about Do guidelines for treating chest disease in children use Cochrane Reviews effectively?: a systematic review.

Growth and nutrition in children with Ataxia telangiectasia (2016)
Journal Article
Stewart, E., Prayle, A. P., Tooke, A., Pasalodos, S., Suri, M., Bush, A., & Bhatt, J. (in press). Growth and nutrition in children with Ataxia telangiectasia. Archives of Disease in Childhood, 101(12), https://doi.org/10.1136/archdischild-2015-310373

Background: Ataxia telangiectasia (A-T) is a rare multisystem disease with high early mortality from lung disease and cancer. Nutritional failure adversely impacts outcomes in many respiratory diseases. Several factors influence nutrition in children... Read More about Growth and nutrition in children with Ataxia telangiectasia.

The pharmacokinetics and toxicity of morning vs. evening tobramycin dosing for pulmonary exacerbations of cystic fibrosis: A randomised comparison (2015)
Journal Article
Smyth, A., Knox, A., Prayle, A., Jain, K., Touw, D., Koch, B., …Smyth, A. R. (2016). The pharmacokinetics and toxicity of morning vs. evening tobramycin dosing for pulmonary exacerbations of cystic fibrosis: A randomised comparison. Journal of Cystic Fibrosis, 15(4), 510-517. https://doi.org/10.1016/j.jcf.2015.07.012

Background: Circadian variation in renal toxicity of aminoglycosides has been demonstrated in animal and human studies. People with CF are frequently prescribed aminoglycosides. Altered pharmacokinetics of aminoglycosides are predictive of toxicity.... Read More about The pharmacokinetics and toxicity of morning vs. evening tobramycin dosing for pulmonary exacerbations of cystic fibrosis: A randomised comparison.

Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis (2015)
Journal Article
Hurley, M., Prayle, A., & Flume, P. (in press). Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis. Cochrane Database of Systematic Reviews, 2015(7), Article CD009730. https://doi.org/10.1002/14651858.CD009730.pub2

BACKGROUND: Cystic fibrosis is a multi-system disease characterised by the production of thick secretions causing recurrent pulmonary infection, often with unusual bacteria. Intravenous antibiotics are commonly used in the treatment of acute deterior... Read More about Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis.

Target renal damage: the microvascular associations of increased aortic stiffness in patients with COPD (2013)
Journal Article
John, M., Hussain, S., Prayle, A., Simms, R., Cockroft, J. R., & Bolton, C. E. (2013). Target renal damage: the microvascular associations of increased aortic stiffness in patients with COPD. Respiratory Research, 14(31), https://doi.org/10.1186/1465-9921-14-31

Background Although renal impairment has been described in COPD, there is opportunity to evaluate further to determine nature and consider optimal management. Increased aortic stiffness, as seen in COPD, leads to reduced buffering of pulsatile flow.... Read More about Target renal damage: the microvascular associations of increased aortic stiffness in patients with COPD.

Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov: cross sectional study (2012)
Journal Article
Prayle, A., Hurley, M., & Smyth, A. R. (2012). Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov: cross sectional study. BMJ, 2011(344), Article d7373. https://doi.org/10.1136/bmj.d7373

Objective To examine compliance with mandatory reporting of summary clinical trial results (within one year of completion of trial) on ClinicalTrials.gov for studies that fall under the recent Food and Drug Administration Amendments Act (FDAAA) legis... Read More about Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov: cross sectional study.

Delayed publications of clinical trials in cystic fibrosis (2011)
Journal Article
Hurley, M., Prayle, A., & Smyth, A. R. (2011). Delayed publications of clinical trials in cystic fibrosis. Journal of Cystic Fibrosis, 11(1), https://doi.org/10.1016/j.jcf.2011.08.004

Background: When the publication of important trial data is delayed, or data are never published, this will prevent the proper practice of evidence based medicine through robust systematic reviews. Clinical trial registries allow researchers to... Read More about Delayed publications of clinical trials in cystic fibrosis.